Polymer-drug Conjugates Market

Polymer-drug Conjugates Market Increase In
Transactional And Analytical Needs Across
Several Industries 2026
Polymer-drug conjugates are nano-sized drug products currently used for treating cancer and
hepatitis. Polymers are now being synthesized to be sensitive to specific enzymes that are
apparent in diseased tissue. Conventional polymers are used in polymer-drug conjugates such as
cellulose and chitin can be degraded through enzymatic activity and acidity. The drugs remain
attached to the polymer and are not activated until the enzymes associated with the diseased
tissue are present. This process significantly minimizes damage to healthy tissues.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2260
Polymer-drug Conjugates Market Driver
New pipeline drugs developed using polymer-drug conjugation are expected to propel growth of
the polymer-drug conjugates market. For instance, in march 2016, National Cancer Institute
(NCI) started undergoing phase II clinical study for CRLX101, a nanoparticle drug conjugate
composed of 20(S)-Camptothecin conjugated to a linear, cyclodextrin-polyethylene glycol-based
polymer, for the treatment of metastatic prostate cancer and the trial is expected to complete
by March 2020.
Polymer-drug Conjugates Market Restraint
Limited use of polymer-drug conjugates is expected to restrain growth of the polymer-drug
conjugates market. For instance, according to an article published in Bioengineering and
Translational Medicine 2016, polymer-drug conjugates are formed by covalent linkage between
the drug and polymer and not all of the drugs have chemical functional groups for covalent
conjugation. Moreover, they offer triggered drug release only at the tumor tissue or cell.
Lack of standard and optimized preclinical or clinical protocols to evaluate polymer-drug
conjugate stability, tumor penetration, metabolism, and toxicity are hindering growth of the
polymer-drug conjugates market.
Polymer-drug Conjugates Market – Regional Analysis
On the basis of region, the global polymer-drug conjugates market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is projected to hold dominant position in the global polymer-drug conjugates
market due to increase in number of clinical trials in the U.S. For instance, in January 2018,
Apellis Pharmaceuticals announced to conduct phase III clinical study for APL-2 in the U.S.
APL-2 is a synthetic cyclic peptide drug conjugated to a polyethylene glycol polymer for the
treatment of geographic atrophy associated with age-related macular degeneration.
Furthermore, increasing research on novel Drug Delivery Systems (DDS) in Asia Pacific is
expected to contribute to significant growth of the polymer drug conjugates market in the
region during the forecast period. For instance, in August 2018, Osaka University, in
collaboration with Tokyo Institute of Technology, Japan, developed a DDS using polyethylene
glycol and polylysine block copolymer, with ubenimex conjugate (PEG-b-PLys (Ube). Intravenous
injection of ubenimex with these polymers in mice, found to reduce the tumor size significantly.
Such results are expected to be a positive traction for growth of the market during the forecast
period.
Report includes chapters which deeply display the following deliverable about industry :
• Polymer-drug Conjugates Market Research Objective and Assumption
• Polymer-drug Conjugates Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Polymer-drug Conjugates Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Polymer-drug Conjugates Market, By Regions
• Polymer-drug Conjugates Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Polymer-drug Conjugates Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Polymer-drug Conjugates Market Manufacturing Cost Analysis including Key Raw Materials
and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Polymer-drug Conjugates Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Inquire Here Before Purchase of Research Report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/2260
Key players operating in polymer-drug conjugates market include, Access Pharma, Abeona
Therapeutics, Inc., ADAMA India Private Limited, Avadel., GlaxoSmithKline plc. JenKem
Technology USA, Lipotek, Sansheng Pharmaceutical Group, Landec Corporation, and Gowan
Company.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Polymer-drug conjugates are nano-sized drug products currently used for treating cancer and hepatitis.

Download Report